EndoSpan

The flagship product is the NEXUS® Aortic Arch Stent Graft System, the first CE-approved, off-the-shelf branched endovascular solution for the aortic arch. This modular system is designed to address complex anatomies and provide a stable, minimally invasive repair. Key features include a main module with an integrated branch for the brachiocephalic artery, an ascending aorta component shaped for natural alignment, and a proprietary "Dock and Lock" mechanism to prevent module separation. The system's lower profile allows for insertion into smaller vessels, and it is designed to mitigate the risk of stroke. The company received CE Mark approval for NEXUS® in March 2019 and FDA Breakthrough Device Designation in April 2020. EndoSpan is actively pursuing FDA approval through its TRIOMPHE clinical study, having completed enrollment for the primary arm in late 2024.

Alon Shalev, a founder of EndoSpan, has also established other medical technology companies, including QART Medical and Paindure, indicating a background in serial entrepreneurship within the life sciences field. The management team includes CEO Kevin Mayberry and other executives with extensive experience in the medical device industry at companies like Medtronic, Johnson & Johnson, and Neovasc. This collective expertise is focused on advancing endovascular treatments for patient groups that have been historically underserved by minimally invasive options. Keywords: EndoSpan, NEXUS Aortic Arch Stent Graft, endovascular aortic repair, aortic arch aneurysm, aortic dissection, medical device, stent graft system, minimally invasive surgery, cardiovascular, Herzliya, Alon Shalev, Rafi Benary, Artivion, CE Mark, FDA approval, TRIOMPHE study, vascular surgery, thoracic aortic repair, off-the-shelf stent, Dock and Lock, health tech, life sciences